Skip to main content
Clinical Trials/NCT02704793
NCT02704793
Completed
Not Applicable

Assessing Clinical Effectiveness of Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) on Severity of Motor Signs of Essential Tremor

Mashhad University of Medical Sciences1 site in 1 country23 target enrollmentApril 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Essential Tremor
Sponsor
Mashhad University of Medical Sciences
Enrollment
23
Locations
1
Primary Endpoint
change in score of Fahn-Tolosa-Marin scale
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Essential tremor (ET) is a low-mortality, though truly burdensome and debilitating condition which is known to be the second most common movement disorder of the adult population only after restless legs syndrome. The prevalence of the disorder in all age groups has been estimated to be 0.9%. Repetitive transcranial magnetic stimulation (rTMS) is an almost safe technique which has been used in diagnosis and treatment of many neurologic and psychiatric conditions. Recent studies have shown that cerebellum has a significant role in development of ET and that rTMS could exert therapeutic effects on its motor symptoms. In this study researchers will recruit at least 30 subjects among patients visiting at the Specialty Clinic of Mashhad Medical University according to researchers exclusion and inclusion criteria and after signing a written informed consent, will randomly be assigned to either real or sham rTMS. On the real rTMS arm, patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days and sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS. Subject's ear will be protected with earplugs during both real and sham stimulations. After 2 months of follow-up, patients will undergo crossover and receive the other treatment as described above. Patients would be assessed using Fahn-Tolosa-Marin scale at the baseline and again on days 5, 12, and 30 after each real or sham treatment session by a blinded researcher. Data will be analysed by another researcher who is also blind.

Registry
clinicaltrials.gov
Start Date
April 2016
End Date
May 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nahid Olfati

Dr

Mashhad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • having a diagnosis of essential tremor (ET) based on Movement Disorder Society criteria, involving at least one hand.
  • 18 years or above
  • cognitively eligible to give informed consent of participation in the trial.

Exclusion Criteria

  • Cardiac pace-maker or other implanted magnetic device or having other contraindications of performing a routine non-contrast MRI
  • skin defect at the occipital area preventing placement of a coil
  • Currently pregnant or plan for pregnancy in the next 6 months
  • History of seizure
  • Other comorbid medical conditions capable of producing or enhancing tremor
  • advanced cardiac, renal, hepatic or other disabling conditions making patient physical unable to participate in examination and receiving the intervention
  • Use of new drugs with potential effect on tremor

Outcomes

Primary Outcomes

change in score of Fahn-Tolosa-Marin scale

Time Frame: at the baseline and on days 5, 12, and 30 after each real or sham treatment session.

Study Sites (1)

Loading locations...

Similar Trials